PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Artelo Biosciences, Inc. (ARTL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS04301G2012
CUSIP04301G201
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$4.72M
EPS-$3.33
EBITDA (TTM)-$7.44M
Year Range$1.15 - $2.90
Target Price$16.67
Short %0.59%
Short Ratio1.04

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Artelo Biosciences, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Artelo Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%20.00%NovemberDecember2024FebruaryMarchApril
-9.50%
17.39%
ARTL (Artelo Biosciences, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Artelo Biosciences, Inc. had a return of -6.07% year-to-date (YTD) and -51.83% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-6.07%5.29%
1 month-10.54%-2.47%
6 months-8.04%16.40%
1 year-51.83%20.88%
5 years (annualized)-61.13%11.60%
10 years (annualized)N/A10.43%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-0.00%10.00%-3.90%
2023-23.16%-15.41%11.74%1.45%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ARTL is 18, indicating that it is in the bottom 18% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of ARTL is 1818
Artelo Biosciences, Inc.(ARTL)
The Sharpe Ratio Rank of ARTL is 1515Sharpe Ratio Rank
The Sortino Ratio Rank of ARTL is 1717Sortino Ratio Rank
The Omega Ratio Rank of ARTL is 1616Omega Ratio Rank
The Calmar Ratio Rank of ARTL is 2121Calmar Ratio Rank
The Martin Ratio Rank of ARTL is 2121Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Artelo Biosciences, Inc. (ARTL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ARTL
Sharpe ratio
The chart of Sharpe ratio for ARTL, currently valued at -0.72, compared to the broader market-2.00-1.000.001.002.003.00-0.73
Sortino ratio
The chart of Sortino ratio for ARTL, currently valued at -0.93, compared to the broader market-4.00-2.000.002.004.00-0.93
Omega ratio
The chart of Omega ratio for ARTL, currently valued at 0.87, compared to the broader market0.501.001.500.87
Calmar ratio
The chart of Calmar ratio for ARTL, currently valued at -0.51, compared to the broader market0.001.002.003.004.005.00-0.51
Martin ratio
The chart of Martin ratio for ARTL, currently valued at -1.16, compared to the broader market0.0010.0020.0030.00-1.16
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.79, compared to the broader market-2.00-1.000.001.002.003.001.79
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.61, compared to the broader market-4.00-2.000.002.004.002.61
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.31
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.36, compared to the broader market0.001.002.003.004.005.001.36
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current Artelo Biosciences, Inc. Sharpe ratio is -0.73. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.73
1.79
ARTL (Artelo Biosciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Artelo Biosciences, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-99.59%
-4.42%
ARTL (Artelo Biosciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Artelo Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Artelo Biosciences, Inc. was 99.64%, occurring on Nov 17, 2023. The portfolio has not yet recovered.

The current Artelo Biosciences, Inc. drawdown is 99.59%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.64%Jan 19, 20181219Nov 17, 2023
-20%Dec 11, 20172Dec 21, 20171Jan 2, 20183

Volatility

Volatility Chart

The current Artelo Biosciences, Inc. volatility is 14.41%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%NovemberDecember2024FebruaryMarchApril
14.41%
3.35%
ARTL (Artelo Biosciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Artelo Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items